P2, N=40, Active, not recruiting, University of Colorado, Denver | Recruiting --> Active, not recruiting

P3, N=96, Not yet recruiting, Nationwide Children's Hospital

P1, N=9, Terminated, Wake Forest University Health Sciences | N=27 --> 9 | Recruiting --> Terminated; Terminated due to low accruals

P2, N=48, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=20, Recruiting, Zhejiang Cancer Hospital

To study resistance mechanisms, we developed the organoid drug resistance assay (ODR-test) with patient-derived organoids from our ovarian cancer biobank and identified sustained phenotypic reprogramming and cellular plasticity of organoids under carboplatin pressure as a conserved mechanism irrespective of the basal resistance level. Additionally, we found that KRT17 expression status (K-score) is a significant negative prognostic histopathological biomarker in a large cohort (N = 384) of patients with advanced HGSOC. In organoids, increased KRT17 levels enhanced sensitivity to PI3K/Akt inhibitors alpelisib and afuresertib, highlighting the potential of KRT17 as a stratification biomarker for targeted therapies.

PIGK functions as a potential oncogenic driver in HNC with prognostic and therapeutic relevance. Its association with FAM20C, taxane response, and modulation of fibroblast activation provides insights into PIGK-mediated oncogenesis and may inform patient stratification strategies.

As the use of androgen receptor pathway inhibitors (ARPIs), with or without docetaxel, prior to the development of castration-resistant disease is increasing, the number of subsequent therapy options for mCRPC is limited.Poly (ADP-ribose) polymerase (PARP) inhibitors are one treatment option approved in Canada for patients with mCRPC and mutations in BRCA1/BRCA2 or other homologous recombination repair (HRR) genes...This can be difficult to manage in mCRPC, as common disease and patient characteristics, as well as prior therapy, also contribute to an increased risk of anemia. Appropriate management of anemia is important for maintaining quality of life; however, there is a paucity of data and guidelines to inform clinicians on how to best prevent and manage anemia associated with PARP inhibitor use in mCRPC.This narrative review and expert opinion provides key strategies for managing anemia related to PARP inhibitor use in mCRPC through prevention, monitoring, and supportive care.

IMRT combined with docetaxel and cisplatin chemotherapy significantly improves the prognosis of advanced SNC. Treatment modality, patient age, tumor differentiation, lymph node status, and molecular markers are all independent prognostic factors, indicating the potential for individualized treatment strategies under comprehensive assessment.

Trial registration: Chictr.org.cn, ChiCTR2200065547. Registered in 2022-11-08, https://www.chictr.org.cn/showproj.html?proj=183439.

Early findings suggest letrozole is well tolerated and may represent a viable therapeutic option for hormone receptor-positive LGSCO. Ongoing molecular and clinical analyses will clarify its role in this rare subtype.

CDH13 is highly expressed in HCC and may promote angiogenesis, immune evasion, and metabolic reprogramming via the FOXA1-CDH13 axis, suggesting its potential as a therapeutic target.